<p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）周四股价上涨了 8.5%。该公司股价最高达到 5.67 美元，最后交易价格为 5.7190 美元。在午盘交易中，共成交 301,220 股，较平均交易量 1,448,313 股下降了 79%。该股票此前收盘价为 5.27 美元。</p>
<p>获取 <strong>Organogenesis</strong> 警报：</p>
<h2>分析师评级上调与下调</h2>
<p>几位分析师最近对 ORGO 股票发布了报告。华尔街 Zen 在 11 月 8 日的研究报告中将 Organogenesis 的评级从 “持有” 上调至 “强力买入”。BTIG 研究在周一重申了 “买入” 评级，并对 Organogenesis 的股票设定了 9.00 美元的目标价。最后，Weiss Ratings 在周一的报告中重申了对 Organogenesis 股票的 “卖出（d+）” 评级。两位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 8.00 美元。</p>
<p><strong>获取我们最新的 Organogenesis 股票分析</strong></p>
<h2>Organogenesis 价格表现</h2>
<p>该公司的市值为 7.1768 亿美元，市盈率为-47.04，贝塔值为 1.47。该股票的 50 日简单移动平均线为 4.81 美元，200 日简单移动平均线为 4.48 美元。该公司的债务与股本比率为 0.01，速动比率为 2.88，流动比率为 3.32。</p>
<p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）于 11 月 6 日（周四）发布了其财报。该公司报告本季度每股收益为 0.18 美元，超出分析师共识预期的 0.07 美元，超出幅度为 0.11 美元。该季度的营业收入为 1.5086 亿美元，而分析师预期为 1.3410 亿美元。Organogenesis 的净利润率为-1.30%，股本回报率为 4.01%。股票研究分析师预计 Organogenesis 在本财年将发布-0.07 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在相关消息中，董事 Glenn H. Nussdorf 于 11 月 26 日（周三）出售了 187,957 股该股票。股份以平均价格 5.29 美元出售，总交易额为 994,292.53 美元。出售完成后，该董事在公司持有 2,765,591 股，价值 14,629,976.39 美元。这代表其持股减少了 6.36%。该出售在向证券交易委员会提交的文件中披露，文件可在 SEC 网站上查阅。在过去的九十天里，内部人士已出售 300,000 股公司股票，价值 1,592,120 美元。33.00% 的股票由公司内部人士持有。</p>
<h2>对 Organogenesis 的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Quarry LP 在第三季度收购了 Organogenesis 的新股份，价值约 25,000 美元。阿拉斯加州财政部在第三季度购买了 Organogenesis 的新股份，价值约 25,000 美元。Farther Finance Advisors LLC 在第二季度收购了 Organogenesis 的新股份，价值约 35,000 美元。Ground Swell Capital LLC 在第二季度收购了 Organogenesis 的新股份，价值 39,000 美元。最后，Regent Peak Wealth Advisors LLC 在第三季度收购了 Organogenesis 的新股份，价值 51,000 美元。目前 49.57% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Organogenesis</h2>
<p>（获取免费报告）</p>
<p>Organogenesis Holdings Inc 是一家再生医学公司，开发、制造和商业化用于美国先进伤口护理、外科和运动医学市场的解决方案。该公司的先进伤口护理产品包括 Affinity，一种保留了活细胞、生长因子/细胞因子和原生组织中 ECM 蛋白的羊膜；Novachor，一种保留了活细胞、生长因子/细胞因子和原生组织中 ECM 蛋白的绒毛膜；Apligraf，一种生物工程活细胞疗法，产生多种细胞因子和生长因子；Dermagraft，一种生物工程产品，产生人类胶原蛋白、ECM、蛋白质、细胞因子和生长因子；NuShield，脱水的胎盘组织覆盖羊膜和绒毛膜以保持海绵/中间层完整；以及 PuraPly AM，一种抗菌屏障，能够实现适应性和液体排出。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Organogenesis</li>
<li>每月分红股票的利与弊</li>
<li>Dollar General 的转机可能会在 2026 年推动股价上涨</li>
<li>零售股票投资解析</li>
<li>不要对 AppLovin 下赌注：反对空头的理由</li>
<li>什么是支撑位？</li>
<li>美光第一季度业绩表明 “人工智能泡沫远未破裂”</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Organogenesis 吗？</h2>
<p>在你考虑投资 Organogenesis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Organogenesis 并不在名单上。</p>
<p>虽然 Organogenesis 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ORGO

<p>Organogenesis（纳斯达克代码：ORGO）股价上涨 8.5%，至 5.7190 美元，成交量为 301,220 股，较平均成交量下降 79%。分析师的评级意见不一：华尔街 Zen 将评级上调至 “强力买入”，BTIG Research 重申 “买入” 评级，目标价为 9 美元，而 Weiss Ratings 维持 “卖出（d+）” 评级。该公司报告第三季度每股收益为 0.18 美元，超出预期。内部人士 Glenn H. Nussdorf 出售了 187,957 股。对冲基金和机构投资者持有该股票的 49.57%</p>

<p>Organogenesis (NASDAQ:ORGO - Get Free Report) shares traded up 8.5% on Thursday . The company traded as high as $5.67 and last traded at $5.7190. 301,220 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 1,448,313 shares. The stock had previously closed at $5.27.</p>
<div class="lb-trans"><p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）周四股价上涨了 8.5%。该公司股价最高达到 5.67 美元，最后交易价格为 5.7190 美元。在午盘交易中，共成交 301,220 股，较平均交易量 1,448,313 股下降了 79%。该股票此前收盘价为 5.27 美元。</p>
</div><p>Get <strong>Organogenesis</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Organogenesis</strong> 警报：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several analysts recently issued reports on ORGO shares. Wall Street Zen raised Organogenesis from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, November 8th. BTIG Research restated a &#34;buy&#34; rating and issued a $9.00 price objective on shares of Organogenesis in a report on Monday. Finally, Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of Organogenesis in a report on Monday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus target price of $8.00.</p>
<div class="lb-trans"><p>几位分析师最近对 ORGO 股票发布了报告。华尔街 Zen 在 11 月 8 日的研究报告中将 Organogenesis 的评级从 “持有” 上调至 “强力买入”。BTIG 研究在周一重申了 “买入” 评级，并对 Organogenesis 的股票设定了 9.00 美元的目标价。最后，Weiss Ratings 在周一的报告中重申了对 Organogenesis 股票的 “卖出（d+）” 评级。两位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 8.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Organogenesis</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Organogenesis 股票分析</strong></p>
</div><h2>Organogenesis Price Performance</h2>
<div class="lb-trans"><h2>Organogenesis 价格表现</h2>
</div><p>The firm has a market cap of $717.68 million, a price-to-earnings ratio of -47.04 and a beta of 1.47. The stock's 50 day simple moving average is $4.81 and its 200-day simple moving average is $4.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32.</p>
<div class="lb-trans"><p>该公司的市值为 7.1768 亿美元，市盈率为-47.04，贝塔值为 1.47。该股票的 50 日简单移动平均线为 4.81 美元，200 日简单移动平均线为 4.48 美元。该公司的债务与股本比率为 0.01，速动比率为 2.88，流动比率为 3.32。</p>
</div><p>Organogenesis (NASDAQ:ORGO - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analysts' expectations of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. Equities research analysts anticipate that Organogenesis will post -0.07 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）于 11 月 6 日（周四）发布了其财报。该公司报告本季度每股收益为 0.18 美元，超出分析师共识预期的 0.07 美元，超出幅度为 0.11 美元。该季度的营业收入为 1.5086 亿美元，而分析师预期为 1.3410 亿美元。Organogenesis 的净利润率为-1.30%，股本回报率为 4.01%。股票研究分析师预计 Organogenesis 在本财年将发布-0.07 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, Director Glenn H. Nussdorf sold 187,957 shares of the stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $5.29, for a total transaction of $994,292.53. Following the completion of the sale, the director owned 2,765,591 shares in the company, valued at $14,629,976.39. This represents a 6.36% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 300,000 shares of company stock valued at $1,592,120. 33.00% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Glenn H. Nussdorf 于 11 月 26 日（周三）出售了 187,957 股该股票。股份以平均价格 5.29 美元出售，总交易额为 994,292.53 美元。出售完成后，该董事在公司持有 2,765,591 股，价值 14,629,976.39 美元。这代表其持股减少了 6.36%。该出售在向证券交易委员会提交的文件中披露，文件可在 SEC 网站上查阅。在过去的九十天里，内部人士已出售 300,000 股公司股票，价值 1,592,120 美元。33.00% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Organogenesis</h2>
<div class="lb-trans"><h2>对 Organogenesis 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in Organogenesis in the third quarter worth about $25,000. State of Alaska Department of Revenue bought a new position in shares of Organogenesis during the 3rd quarter worth about $25,000. Farther Finance Advisors LLC acquired a new stake in shares of Organogenesis during the 2nd quarter worth approximately $35,000. Ground Swell Capital LLC acquired a new stake in Organogenesis during the second quarter worth $39,000. Finally, Regent Peak Wealth Advisors LLC acquired a new position in shares of Organogenesis in the 3rd quarter valued at $51,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Quarry LP 在第三季度收购了 Organogenesis 的新股份，价值约 25,000 美元。阿拉斯加州财政部在第三季度购买了 Organogenesis 的新股份，价值约 25,000 美元。Farther Finance Advisors LLC 在第二季度收购了 Organogenesis 的新股份，价值约 35,000 美元。Ground Swell Capital LLC 在第二季度收购了 Organogenesis 的新股份，价值 39,000 美元。最后，Regent Peak Wealth Advisors LLC 在第三季度收购了 Organogenesis 的新股份，价值 51,000 美元。目前 49.57% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Organogenesis</h2>
<div class="lb-trans"><h2>关于 Organogenesis</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.</p>
<div class="lb-trans"><p>Organogenesis Holdings Inc 是一家再生医学公司，开发、制造和商业化用于美国先进伤口护理、外科和运动医学市场的解决方案。该公司的先进伤口护理产品包括 Affinity，一种保留了活细胞、生长因子/细胞因子和原生组织中 ECM 蛋白的羊膜；Novachor，一种保留了活细胞、生长因子/细胞因子和原生组织中 ECM 蛋白的绒毛膜；Apligraf，一种生物工程活细胞疗法，产生多种细胞因子和生长因子；Dermagraft，一种生物工程产品，产生人类胶原蛋白、ECM、蛋白质、细胞因子和生长因子；NuShield，脱水的胎盘组织覆盖羊膜和绒毛膜以保持海绵/中间层完整；以及 PuraPly AM，一种抗菌屏障，能够实现适应性和液体排出。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Organogenesis</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Dollar General's Turnaround Could Send the Stock Higher in 2026</li>
<li>Retail Stocks Investing, Explained</li>
<li>Don’t Bet Against AppLovin: The Case Against the Shorts</li>
<li>What is a support level?</li>
<li>Micron’s Q1 Results Say “AI Bubble Is Far From Bursting”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Organogenesis</li>
<li>每月分红股票的利与弊</li>
<li>Dollar General 的转机可能会在 2026 年推动股价上涨</li>
<li>零售股票投资解析</li>
<li>不要对 AppLovin 下赌注：反对空头的理由</li>
<li>什么是支撑位？</li>
<li>美光第一季度业绩表明 “人工智能泡沫远未破裂”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organogenesis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Organogenesis 吗？</h2>
</div><p>Before you consider Organogenesis, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Organogenesis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Organogenesis 并不在名单上。</p>
</div><p>While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Organogenesis 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Organogenesis（NASDAQ:ORGO）股价上涨 8.5% - 事情经过